128 related articles for article (PubMed ID: 29466863)
1. OBSERVE-5: Comparison of Etanercept-Treated Psoriasis Patients From Canada and the United States.
Papp KA; Bourcier M; Poulin Y; Lynde CW; Gilbert M; Poulin-Costello M; Billen L; Isaila M
J Cutan Med Surg; 2018; 22(3):297-303. PubMed ID: 29466863
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.
Tyring S; Gordon KB; Poulin Y; Langley RG; Gottlieb AB; Dunn M; Jahreis A
Arch Dermatol; 2007 Jun; 143(6):719-26. PubMed ID: 17576937
[TBL] [Abstract][Full Text] [Related]
3. OBSERVE-5 interim analysis: an observational postmarketing safety registry of etanercept for the treatment of psoriasis.
Kimball AB; Pariser D; Yamauchi PS; Menter A; Teller CF; Shi Y; Yong M; Creamer K; Hooper M; Aras G; Kricorian G; Gelfand JM
J Am Acad Dermatol; 2013 May; 68(5):756-64. PubMed ID: 23357569
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE).
Reich K; Gooderham M; Green L; Bewley A; Zhang Z; Khanskaya I; Day RM; Goncalves J; Shah K; Piguet V; Soung J
J Eur Acad Dermatol Venereol; 2017 Mar; 31(3):507-517. PubMed ID: 27768242
[TBL] [Abstract][Full Text] [Related]
5. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast.
Bagel J; Samad AS; Stolshek BS; Aras GA; Chung JB; Kricorian G; Kircik LH
J Drugs Dermatol; 2018 Oct; 17(10):1078-1082. PubMed ID: 30365588
[TBL] [Abstract][Full Text] [Related]
6. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H; van de Kerkhof PC; Strohal R; Kubanov A; Valenzuela F; Lee JH; Yakusevich V; Chimenti S; Papacharalambous J; Proulx J; Gupta P; Tan H; Tawadrous M; Valdez H; Wolk R;
Lancet; 2015 Aug; 386(9993):552-61. PubMed ID: 26051365
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data.
Strober B; Leonardi C; Papp KA; Mrowietz U; Ohtsuki M; Bissonnette R; Ferris LK; Paul C; Lebwohl M; Braun DK; Mallbris L; Wilhelm S; Xu W; Ljungberg A; Acharya N; Reich K
J Am Acad Dermatol; 2017 Mar; 76(3):432-440.e17. PubMed ID: 27889292
[TBL] [Abstract][Full Text] [Related]
9. OBSERVE-5: observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results.
Kimball AB; Rothman KJ; Kricorian G; Pariser D; Yamauchi PS; Menter A; Teller CF; Aras G; Accortt NA; Hooper M; Rice KC; Gelfand JM
J Am Acad Dermatol; 2015 Jan; 72(1):115-22. PubMed ID: 25264239
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of etanercept monotherapy for moderate-to-severe plaque psoriasis: A prospective 12-week follow-up study.
Xie F; Wang R; Zhao ZG; Meng XF; Lin BW; Yang J; Wang WJ; Ding XY; Yang Y; Zhao H; Li CX; Li HJ; Zhou Y
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):943-947. PubMed ID: 29270758
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
12. Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population.
Papp KA; Poulin Y; Bissonnette R; Bourcier M; Toth D; Rosoph L; Poulin-Costello M; Setterfield M; Syrotuik J
J Am Acad Dermatol; 2012 Feb; 66(2):e33-45. PubMed ID: 20850895
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis.
Paller AS; Siegfried EC; Pariser DM; Rice KC; Trivedi M; Iles J; Collier DH; Kricorian G; Langley RG
J Am Acad Dermatol; 2016 Feb; 74(2):280-7.e1-3. PubMed ID: 26775775
[TBL] [Abstract][Full Text] [Related]
14. One-year, multicenter, open-label, single-arm study evaluating the safety and effectiveness of etanercept for the treatment of moderate-to-severe plaque psoriasis in a Canadian population.
Vender R; Lynde C; Gilbert M; Ho V; Sapra S; Poulin-Costello M
J Cutan Med Surg; 2013; 17(2):129-38. PubMed ID: 23582167
[TBL] [Abstract][Full Text] [Related]
15. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.
Griffiths CE; Reich K; Lebwohl M; van de Kerkhof P; Paul C; Menter A; Cameron GS; Erickson J; Zhang L; Secrest RJ; Ball S; Braun DK; Osuntokun OO; Heffernan MP; Nickoloff BJ; Papp K;
Lancet; 2015 Aug; 386(9993):541-51. PubMed ID: 26072109
[TBL] [Abstract][Full Text] [Related]
16. Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.
Bourcier M; Papp KA; Gulliver WP; Poulin Y; Barber K; Poulin-Costello M; Shelton J
J Cutan Med Surg; 2015; 19(6):561-9. PubMed ID: 25951825
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.
Reich K; Gooderham M; Bewley A; Green L; Soung J; Petric R; Marcsisin J; Cirulli J; Chen R; Piguet V
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):397-402. PubMed ID: 29220542
[TBL] [Abstract][Full Text] [Related]
18. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis.
Pariser DM; Leonardi CL; Gordon K; Gottlieb AB; Tyring S; Papp KA; Li J; Baumgartner SW
J Am Acad Dermatol; 2012 Aug; 67(2):245-56. PubMed ID: 22015149
[TBL] [Abstract][Full Text] [Related]
19. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, randomized, open-label pilot trial assessing the efficacy and safety of etanercept 50 mg twice weekly followed by etanercept 25 mg twice weekly, the combination of etanercept 25 mg twice weekly and acitretin, and acitretin alone in patients with moderate to severe psoriasis.
Lee JH; Youn JI; Kim TY; Choi JH; Park CJ; Choe YB; Song HJ; Kim NI; Kim KJ; Lee JH; Yoo HJ
BMC Dermatol; 2016 Jul; 16(1):11. PubMed ID: 27455955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
